This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe
Europe's premier partnering event
November 3–5, 2025 | Vienna, AustriaNovember 11–12, 2025 | Digital Partnering
Menu
Biopharma Partnering and Financing Trends, H1 2020
By Deborah GravelleShareshare

For the fifth year, Pharma Intelligence has analyzed the types of alliances, the scope of dealmaking activity, and the myriad of opportunities that continue to drive drug development in the biopharma industry. In their new white paper, Biopharma Partnering and Financing Trends, H1 2020, we learn the impact COVID-19 has had on the industry and how the first half of 2020 compares with the first half of 2019.

Just cover of Partnering Trends report

Download

Read about:

Deal volume

Financial value of the deals made

Reasons why deal volumes changed from one quarter to another

Highest partnership therapy areas

Impact COVID-10 had on partnership activity

The effect announced milestones had on deals

Drug Development
BIO-Europe 2020
Partner

Related news

Drug Development

Biotech Startups: How to Succeed in a COVID-19 World

Taking a biotech company from concept, through clinical trials, and ultimately to market requires a perfect storm of good science, a sound investment, and the right management. This ebook is here to guide startups through this journey.
Drug Development

Interview: Importance of diversity and partnering in global life sciences

ATLATL Innovation Cluster (IC) in the heart of Zhangjiang Pharma Valley. Its Founder and CEO, Dr. P.C. Zhu, designed it to be a launchpad for high-potential life sciences in China. In this interview with EBD Group he discusses the opportunities ATLATL provides and the importance of partnering in the life science industry.
Drug Development

Video Interview - Johnson & Johnson’s approach to external innovation

William N. Hait, MD, PhD, Global Head at Johnson & Johnson External Innovation gives an exclusive interview to Lucie Ellis, Executive Editor of In Vivo, Pharma Intelligence, ahead of ChinaBio® Partnering Forum Digital.